Name: Gadodiamide

---

Type: small molecule

---

Groups: approved

---

Indication: For intravenous use in MRI to visualize lesions with abnormal vascularity (or those thought to cause abnormalities in the blood-brain barrier) in the brain (intracranial lesions), spine, and associated tissues.

---

Accession Number: DB00225 ( APRD00990)

---

Description: Gadodiamide is a gadolinium based contrast agent used in MR imaging procedures to assist in the visualization of blood vessels. It is commonly marketed under the trade name Omniscan. [Wikipedia]

---

Structure:

---

Prescription Products:

Name	Dosage	Strength	Route	Marketing Start	Marketing End	Country
Omniscan	solution	287 mg	intravenous	25-03-1997		Canada
Omniscan	injection	287 mg/mL	intravenous	19-04-2002		US
Omniscan	injection	287 mg/mL	intravenous	29-07-2005		US
Omniscan Liq IV 287mg/ml	liquid	287 mg	intravenous	31-12-1994	30-07-1997	Canada

---

Generic Prescription Products: Not Available

---

Over the Counter Products: Not Available

---

International Brands

• No Brands

---

Brand Names

• No Brands

---

Brand Mixtures

Brand Name	Ingredients
Omniscan	Gadodiamide
Omniscan	Gadodiamide
Omniscan	Gadodiamide
Omniscan Liq IV 287mg/ml	Gadodiamide

Brand Name	Ingredients
Omniscan	Gadodiamide
Omniscan	Gadodiamide
Omniscan	Gadodiamide
Omniscan Liq IV 287mg/ml	Gadodiamide

---

Categories

• No Category

Indication: For intravenous use in MRI to visualize lesions with abnormal vascularity (or those thought to cause abnormalities in the blood-brain barrier) in the brain (intracranial lesions), spine, and associated tissues.

---

Pharmacodynamics: Not Available

---

Mechanism of action: Based on the behavior of protons when placed in a strong magnetic field, which is interpreted and transformed into images by magnetic resonance (MR) instruments. Paramagnetic agents have unpaired electrons that generate a magnetic field about 700 times larger than the proton's field, thus disturbing the proton's local magnetic field. When the local magnetic field around a proton is disturbed, its relaxation process is altered. MR images are based on proton density and proton relaxation dynamics. MR instruments can record 2 different relaxation processes, the T1 (spin-lattice or longitudinal relaxation time) and the T2 (spin-spin or transverse relaxation time). In magnetic resonance imaging (MRI), visualization of normal and pathological brain tissue depends in part on variations in the radiofrequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in the T2. When placed in a magnetic field, gadodiamide shortens both the T1 and the T2 relaxation times in tissues where it accumulates. At clinical doses, gadodiamide primarily affects the T1 relaxation time, thus producing an increase in signal intensity. Gadodiamide does not cross the intact blood-brain barrier; therefore, it does not accumulate in normal brain tissue or in central nervous system (CNS) lesions that have not caused an abnormal blood-brain barrier (e.g., cysts, mature post-operative scars). Abnormal vascularity or disruption of the blood-brain barrier allows accumulation of gadodiamide in lesions such as neoplasms, abscesses, and subacute infarcts.

---

Absorption: Not Available

---

Volume of distribution:

• 200 ± 61 mL/kg

---

Protein binding: Not Available

---

Metabolism: Not Available

---

Route of elimination: Gadodiamide is eliminated primarily in the urine.

---

Half life: Two-compartment model with mean distribution and elimination half-lives (reported as mean ± SD) of 3.7 ± 2.7 minutes and 77.8 ± 16 minutes, respectively.

---

Clearance: Not Available

---

Toxicity: Not Available

---

Affected organisms

• Not Available

---

SNP Mediated Adverse Drug Reactions

• Not Available

Manufacturers:

• Ge healthcare

---

Packagers:

• Amersham Health Inc.
• GE Healthcare Inc.

---

Dosage forms

Form	Route	Strength
Injection	intravenous	287 mg/mL
Solution	intravenous	287 mg
Liquid	intravenous	287 mg

Form	Route	Strength
Injection	intravenous	287 mg/mL
Solution	intravenous	287 mg
Liquid	intravenous	287 mg

---

Prices

Unit description	Cost	Unit
Omniscan 287 mg/ml bottle	$6.49	ml
Omniscan 287 mg/ml vial	$6.98	ml
Omniscan prefill plus syringe	$7.02	ml

Unit description	Cost	Unit
Omniscan 287 mg/ml bottle	$6.49	ml
Omniscan 287 mg/ml vial	$6.98	ml
Omniscan prefill plus syringe	$7.02	ml

---

Patents

Country	Patent Number	Approved	Expires (estimated)
1335819	Canada	1995-06-06	2012-06-06
5362475	United States	1994-11-08	2011-11-08
5560903	United States	1993-10-01	2013-10-01

Drug Interactions

Drug	Interaction

Drug	Interaction

---

Food Interactions:

• Not Available

Kingdom: Organic compounds

---

Super Class: Not Available

---

Class: Not Available

---

Sub Class: Not Available

---

Direct Parent: Not Available

---

Alternative Parents:

• Alpha amino acids
• Carbonyl compounds
• Carboxylic acid salts
• Carboxylic acids
• Hydrocarbon derivatives
• Organic salts
• Organic zwitterions
• Secondary carboxylic acid amides
• Trialkylamines
• Tricarboxylic acids and derivatives

---

substituent:

• Aliphatic acyclic compound
• Alpha-amino acid
• Alpha-amino acid amide
• Amine
• Carbonyl group
• Carboxamide group
• Carboxylic acid
• Carboxylic acid amide
• Carboxylic acid salt
• Hydrocarbon derivative
• Organic salt
• Organic zwitterion
• Organonitrogen compound
• Organooxygen compound
• Secondary carboxylic acid amide
• Tertiary aliphatic amine
• Tertiary amine
• Tricarboxylic acid or derivatives

Synthesis Reference: Not Available

---

General Reference: Not Available

---

External Links:

Resource	Link
RxList	http://www.rxlist.com/cgi/generic3/omniscan.htm

Resource	Link
RxList	http://www.rxlist.com/cgi/generic3/omniscan.htm

---

ATC Codes:

• Array

---

AHFS Codes:

• 92:00.00

---

MSDS: Download